Myeloid lineage switch following chimeric antigen receptor T‐cell therapy in a patient with TCF3‐ZNF384 fusion‐positive B‐lymphoblastic leukemia
Matthew J. Oberley(Caris Life Sciences (United States)), Gordana Raca(Children's Hospital of Los Angeles), Paul S. Gaynon(University of Southern California), Jianling Ji(University of Southern California), Matthew Hiemenz(Foundation Medicine (United States)), Rebecca Gardner(Seattle Children's Hospital), Alan S. Wayne(University of Southern California), Jennifer Han(University of Southern California), Michael A. Pulsipher(Primary Children's Hospital), Maurice R.G. O’Gorman(Children's Hospital of Los Angeles), Deepa Bhojwani(St. Jude Children's Research Hospital)
Cited by 104
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|920